an Acetaldehyde-binding product

An estimated 2% of the population suffer from damage to and functional disorders of the gastric mucosa (atrophic gastritis) caused by a Helicobacter pylori infection or autoimmune disease, which among other things leads to an acid-free stomach (hypo- or achlorhydria).

An acid-free stomach is the primary risk factor in gastric cancer. According to recent research, it is also a significant risk factor in oesophageal cancer.

Additionally, around 10% of the population use regular medications which inhibit or reduce gastric acid secretion, further contributing to the prevalence of achlorhydria.

In a stomach low in acid, microbes (bacteria and yeasts) thrive and produce acetaldehyde from ingested alcohol and sugar. Acetaldehyde produced locally in the stomach increases the risk of cancer.


Reducing the Acetaldehyde risk in patients with Achlorhydria

Acetium® Capsule is a CE marked product developed and patented by Biohit Oyj. It is intended for persons with a low-acid or anacidic stomach.

Acetium capsules include 100mg of natural amino acid as an active ingredient. L-cysteine reacts with acetaldehyde, forming harmless 2-methylthiazolidine-4-carboxylic acid (MTCA) and thus reducing the amount of acetaldehyde in the stomach.

Acetium capsules include matrix granules in which the L-cysteine is bound with a matrix former (Eudragit® RS) and  an inactive excipient. This causes L-cysteine to be released at a sustained rate and locally in the stomach - exactly where acetaldehyde is formed.

  • Matrix granules in a hard HPMC capsule

  • Active ingredient 100mg of plant-derived natural amino-acid L-cysteine made in Germany 

  • CE marked medical device

  • Does not contain animal-derived substances, lactose, gluteine, sugar or allergens

  • Package size 60 capsules

  • Dosage 1-2 capsules with meal



Acetium Capsule related literature:


  1. Maejima R. et al. Inactivation of Carcinogenic Acetaldehyde by Slowly L-Cysteine Releasing Capsule Formulation in Gastric Juice of PPI Treated Volunteers After Intra-Gastric Infusion of Ethanol. Gastroenterology 2014; 146(5): S-507 (Su1955). DDW 2014 Poster abstract Su1955

  2. Hellström PM. et al. L-Cysteine Slow-Release Capsule Formulation in Prevention of Gastric Carcinogenesis Associated With Atrophic Gastritis. Gastroenterology 2014; 146(5):S-315 (Sa1863).  DDW 2014 poster abstract Sa1863 (A538).

  3. Slow-release L-cysteine capsule prevents gastric mucosa exposure to carcinogenic acetaldehyde: results of a randomised single-blinded, cross-over study of Helicobacter-associated atrophic gastritis. Scand J Gastroenterol 2017; 52 (2):230-237.